Trials / Recruiting
RecruitingNCT06696716
ONO-4059 Study in Patients With Steroid-resistant Pemphigus
ONO-4059-10:Multicenter, Placebo-controlled, Randomized, Double-blind, Phase 3 Study in Patients With Steroid-resistant Pemphigus (BRILLIANT Study)
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 34 (estimated)
- Sponsor
- Ono Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
ONO-4059-10:Multicenter, placebo-controlled, randomized, double-blind, Phase 3 study in patients with steroid-resistant pemphigus
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ONO-4059 | Tirabrutinib is a Bruton's Tyrosine Kinase Inhibitor. Tirabrutinib will be administered orally at a dose of 80 mg once daily after a meal (breakfast, lunch, or dinner). |
| DRUG | ONO-4059 placebo | Placebo will be administered orally once daily after a meal (breakfast, lunch, or dinner). |
Timeline
- Start date
- 2022-08-15
- Primary completion
- 2027-09-30
- Completion
- 2029-03-31
- First posted
- 2024-11-20
- Last updated
- 2026-01-07
Locations
25 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT06696716. Inclusion in this directory is not an endorsement.